Do DOACs reduce stroke/SEE, major bleeding, and all-cause death compared to well-controlled warfarin in elderly patients with NVAF?
In a large Japanese registry of elderly NVAF patients, DOAC use was associated with lower rates of stroke, major bleeding, and mortality compared to well-controlled warfarin.
In Japan, a large proportion of elderly and very elderly NVAF patients were receiving DOACs, which was significantly associated with lower rates of stroke/SEE, major bleeding, and all-cause death vs. well-controlled warfarin. History of falls and of catheter ablation were independently associated with stroke/SEE, major bleeding, and all-cause death.
Yamashita et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: